James G. Moe

Oligomerix (United States) — United States

Medicine · Health Sciences

13h-index790citations35works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(25), Cholinesterase and Neurodegenerative Diseases(15), Computational Drug Discovery Methods(9), Neuroscience and Neuropharmacology Research(7), DNA and Nucleic Acid Chemistry(5)

Publications35 total

Therapeutic Treatment With <scp>OLX</scp>‐07010 Inhibited Tau Aggregation and Ameliorated Motor Deficits in an Aged Mouse Model of Tauopathy
Journal of Neurochemistry·2025· 2 citedOpen Access
Acute treatment with OLX‐07010 reduced tau aggregates and upregulated a marker of autophagy with dose dependence in aged P301L tau JNPL3 mice
Alzheimer s & Dementia·2024Open Access
Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice
PLoS ONE·2023· 8 citedOpen Access
Preclinical development of a small molecule inhibitor of tau self‐association for Alzheimer’s disease and related dementias
Alzheimer s & Dementia·2022· 1 citedOpen Access
Identification of pharmacodynamics readouts through acute dosing of a small molecule inhibitor of tau self‐association in a tauopathy mouse model
Alzheimer s & Dementia·2021Open Access
<i>In vivo</i> validation of therapeutic efficacy of a small molecule lead targeting tau self‐association in JNPL3 mice
Alzheimer s & Dementia·2021
In vivo validation of a lead compound targeting tau self‐association in two mouse models of tauopathy
Alzheimer s & Dementia·2020Open Access
<i>In Vivo</i> Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice
Journal of Alzheimer s Disease·2019· 15 citedOpen Access
P4‐698: LINEAR DOSE‐DEPENDENT INHIBITION OF TAU AGGREGATION IN VIVO WITH SMALL MOLECULE
Alzheimer s & Dementia·2019
P4‐222: IN VIVO EFFICACY OF A SMALL MOLECULE INHIBITOR OF TAU OLIGOMER FORMATION IN HTAU MICE
Alzheimer s & Dementia·2018· 1 cited
[P4–589]: CNS DRUG‐LIKE INHIBITORS OF TAU OLIGOMERIZATION
Alzheimer s & Dementia·2017· 1 cited
P1‐084: Small Molecule TAU Oligomerization Inhibitors
Alzheimer s & Dementia·2016· 3 cited
Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory
Scientific Reports·2016· 264 citedOpen Access
P4‐319: Characterization of tool compounds targeting tau oligomers
Alzheimer s & Dementia·2015
P3‐329: Identification of tau oligomer proteolytic activity as a novel target for drug discovery
Alzheimer s & Dementia·2015· 1 citedOpen Access
Isolation and characterization of antibody fragments selective for toxic oligomeric tau
Neurobiology of Aging·2014· 27 citedOpen Access
P4‐212: DRUG DEVELOPMENT OF INHIBITORS OF TAU OLIGOMER FORMATION FOR ALZHEIMER'S DISEASE AND TAUOPATHIES
Alzheimer s & Dementia·2014· 1 cited
P4–423: Small‐molecule lead identification for inhibition of tau oligomer formation
Alzheimer s & Dementia·2013· 2 cited
P1–411: Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between Alzheimer's disease and non‐Alzheimer's specimens
Alzheimer s & Dementia·2013
P1–212: Detection of soluble oligomeric tau with morphology‐specific antibody fragments as a potential diagnostic method for Alzheimer's disease
Alzheimer s & Dementia·2013
page 1 of 2Next →

Frequent Co-authors

Eliot J. Davidowitz(26), Patricia López(11), Patrícia Luciana da Costa Lopez(8), Leslie R. Adrien(7), Heidy Jimenez(6), Peter Davies(6), Pavan Krishnamurthy(5), Huilai Tian(4), Giulia Papiani(4), Daisy Romero(4), Ishita Chatterjee(3), Michael R. Sierks(3), Ottavio Arancio(3), Irina M. Russu(3), G. Ramachandra Reddy(3), Michael P. Stone(3), Dhruv Patel(3), Mauro Fà(2), Daniela Puzzo(2), Jason P. Weisenseel(2)